Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App

Carole H. Sudre^{1,2,3}, Benjamin Murray³, Thomas Varsavsky³, Mark S. Graham³, Rose S. Penfold⁴, Ruth C. Bowyer⁵, Joan Capdevila Pujol⁵, Kerstin Klaser³, Michela Antonelli³, Liane S. Canas³, Erika Molteni³, Marc Modat³, M. Jorge Cardoso³, Anna May⁵, Sajaysurya Ganesh⁵, Richard Davies⁵, Long H Nguyen⁶, David A. Drew⁶, Christina M. Astley⁷, Amit D. Joshi⁶, Jordi Merino^{8,9,10}, Neli Tsereteli¹¹, Tove Fall¹², Maria F. Gomez¹¹, Emma L. Duncan⁴, Cristina Menni⁴, Frances M.K. Williams⁴, Paul W. Franks^{4,11}, Andrew T. Chan⁶, Jonathan Wolf⁵, Sebastien Ourselin^{3*}, Tim Spector^{4*}, Claire J. Steves^{4*}

1 MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences, University College London, WC1E 7HB London

2 Centre for Medical Image Computing, Department of Computer Science, University College London

3 School of Biomedical Engineering & Imaging Sciences, King's College London, SE1 7EU, London UK

4 Department of Twin Research and Genetic Epidemiology, King's College London, Westminster Bridge Road, SE17EH London, UK

5 Zoe Global Limited, 164 Westminster Bridge Road, London SE1 7RW, UK

6 Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, MA, USA

7 Division of Endocrinology & Computational Epidemiology, Boston Children's Hospital, MA, USA

8 Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.

9 Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.

10 Department of Medicine, Harvard Medical School, Boston, MA, USA.

11 Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Sweden

12 Molecular epidemiology, Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala Sweden

* Contributed equally

Corresponding author: Claire J. Steves – Claire.j.steves@kcl.ac.uk

Reports of “Long-COVID”, are rising but little is known about prevalence, risk factors, or

whether it is possible to predict a protracted course early in the disease. We analysed data

from 4182 incident cases of COVID-19 who logged their symptoms prospectively in the COVID

Symptom Study app. 558 (13.3%) had symptoms lasting ≥ 28 days, 189 (4.5%) for ≥ 8 weeks

and 95 (2.3%) for ≥ 12 weeks. Long-COVID was characterised by symptoms of fatigue, headache, dyspnoea and anosmia and was more likely with increasing age, BMI and female sex. Experiencing more than five symptoms during the first week of illness was associated with Long-COVID, OR=3.53 [2.76;4.50]. A simple model to distinguish between short and long-COVID at 7 days, which gained a ROC-AUC of 76%, was replicated in an independent sample of 2472 antibody positive individuals. This model could be used to identify individuals for clinical trials to reduce long-term symptoms and target education and rehabilitation services.

COVID-19 can manifest a wide severity spectrum from asymptomatic to fatal forms¹. A further source of heterogeneity is the duration of symptoms, which could have considerable impact due to the huge scale of the pandemic. Hospitalised patients are well recognised to have lasting dyspnoea and fatigue in particular², yet such patients constitute the ‘tip of the iceberg’ of symptomatic SARS CoV2 disease³. Few studies capture symptoms prospectively in the general population to ascertain with accuracy the duration of illness and the prevalence of long-lasting symptoms.

Here we report a prospective observational cohort study of COVID-19 symptoms in a subset of 4182 users of the COVID Symptom Study app meeting inclusion criteria (see online methods)^{4,5}, compared to matched symptomatic test-negative controls. Briefly, the cases comprised individuals who reported testing positive for SARS-CoV2 by swab testing who started on the app “feeling physically normal” to be able to determine symptom onset. We compare cases with symptoms persisting over 28 days, LC28) and short duration (symptoms lasting less than

10 days, short-COVID). Our previous findings that clusters of symptoms predicted the need for acute care⁶ led us to hypothesize that persistent symptomatology in COVID-19 (Long-COVID) is associated with early symptom patterns which could be used to predict who might be affected. Figure 1 shows the duration of symptoms reported in COVID+ cases (orange) over-laid on age, sex and BMI matched negative-testing symptomatic controls (blue). The overall median symptom duration was 11 days (IQR[6;19]).

Of the 4182 COVID-19 swab positive users, 558 (13.3%) met the LC28 definition (Median 41, IQR[33,63]) of whom 189 (4.5%) met LC56, and 108 (2.6%) LC84. In contrast 1591 (38.0%) had short-COVID (median 6, IQR[4-8]). The proportions were comparable in three countries (LC28: GB 13.3%, USA 16.1%, Sweden 12.1% $p=0.35$; LC56: GB 4.7%, USA 5.5%, Sweden 2.5% $p=0.07$).

Table 1 summarises the descriptive characteristics of the study population stratifying by symptom/disease duration. Age was significantly associated with LC28, rising from 9.9% in 18-49 year-olds to 21.9% in those aged ≥ 70 ($p < 0.0005$), with escalating OR by age decile (Figure 1b, Supplementary Table 2). LC28 disproportionately affected women (14.9%) compared to men (9.5%), although not in the older age-group. Long-COVID affected all socio-economic groups (assessed using Index of Multiple Deprivation), (Supplementary Figure 2). Individuals with Long-COVID were more likely to have required hospital assessment. Asthma was the only/unique pre-existing condition providing significant association with LC28 (OR=2.14 [1.55-2.96]).

Fatigue (97.7%) and headache (91.2%) were the most reported symptoms in those with LC28, followed by anosmia and lower respiratory symptoms, and headache was more often reported intermittently (Figure 2, supplementary Table s1). Free-text additional symptoms were more commonly reported in LC28 cases (81%) compared to Short-COVID (45%), with cardiac symptoms (palpitations, tachycardia) (LC28, 6.1%; short-COVID 0.5% $p < 0.0005$), concentration or memory issues (4.1% vs 0.2%, $p < 0.0005$), tinnitus and earache (3.6% vs 0.2% $p < 0.0005$) and peripheral neuropathy symptoms (pins and needles and numbness) (2% vs 0.5% $p = 0.004$) disproportionately reported in LC28. Most of these symptoms were reported for the first time 3-4 weeks post-symptom onset.

We found two main patterns of symptomatology within LC28: those reporting exclusively fatigue, headache and upper respiratory complaints (shortness of breath, sore throat, persistent cough and loss of smell) and those with additional multi-system complaints, including ongoing fever and gastroenterological symptoms (Supplementary figure 3). In the individuals with long duration (LC28), ongoing fever OR 2.16 [1.50;3.13] and skipped meals OR 2.52 [1.74;3.65] were strong predictors of a hospital visit. Details of the frequency of symptoms persisting beyond 28 and 56 days after disease onset are provided in Supplementary table 3.

Individuals with LC28 were more likely to report relapses (16.0% vs 8.4%) ($p < 0.0005$). In comparison, in the matched group of SARS-CoV2 negative-tested individuals, relapse was reported in 11.5%, and relapse was longer in LC28 (median = 9 [5-18] vs 6 [4-10] days).

We explored how to estimate risk of LC28 among positive individuals from data available early in the disease course. Individuals reporting more than 5 symptoms in the first week (the median number reported) were significantly more likely to go on to experience LC28, (OR=3.95 [3.10;5.04]). This strongest risk factor was predictive in both sexes and all age groups (supplementary Figures 4, a-e).

The five symptoms experienced during the first week most predictive of LC28 in the positive individuals were: fatigue OR=2.83 [2.09;3.83], headache OR=2.62 [2.04;3.37], dyspnoea OR=2.36 [1.91;2.91], hoarse voice OR=2.33 [1.88;2.90] and myalgia OR=2.22 [1.80;2.73] (Figure 3). Similar patterns were observed in both genders. In adults aged over 70, loss of smell (which is less common) was the most predictive of long-COVID OR=7.35 [1.58;34.22] before fever OR=5.51 [1.75;17.36] and hoarse voice OR=4.03 [1.21;13.42] (Supplementary figures 4). Co-occurrence plots of symptoms in short-COVID versus LC28 further illustrate the importance of early multi-symptom involvement (Figure 3c).

We created Random Forest Prediction models using a combination of the first week's symptom reporting, personal characteristics and comorbidities. Using all features, the average ROC AUC was 76.7% (SD=2.5) (Figure 3d) in the classification between short-COVID and LC28. The strongest predictor was age (29.2%) followed by the number of symptoms during the first week (16.3%). Feature importance was relatively similar across age-specific models. However, in the over 70s, early features such as fever, anosmia and comorbidities were important, and may be 'red flags' in older adults (Supplementary figure 6).

To create a model usable in healthcare settings, we simplified the prediction model to include only symptom number in the first week with age, and sex in a logistic regression model obtaining ROC AUC of 76.7% (SD 2.5) (Figure 3d), for which the calibration slope had an average of 1.02 (0.15). When optimising the balance between false positives and false negatives, we obtained a specificity of 73.4% (SD 9.7) and a sensitivity of 68.7% (SD 9.9). Specificity, Sensitivity, PPV and NPV values at different thresholds are presented in Supplementary table 6.

Key predictive findings of our analysis were validated in an independent dataset of 2412 individuals who reported testing antibody positive (but no positive PCR result) for SARS-CoV2 from 2 weeks after symptom onset where, again, the number of symptoms in the first week of illness was the strongest predictor, OR=4.60 [95% CI 3.28; 6.46]. The simple prediction model, was similarly predictive of LC28 in the antibody group, with a ROC-AUC of 75.9% (SD=4.3%) (Figure 3-e).

While this study provides important insights into the disease presentation, any generalisation should be considered carefully. Our study was limited by being confined to app users who were disproportionately female and under-represented those >70years which could increase or decrease our estimate of the extent of Long-COVID respectively and caution is needed in interpreting associations found in smaller population subgroups. Swab test results were self-reported and were all assumed to be RT-PCR, as antigen tests were not available at the time. Applying a weighting following the UK population (see Supplementary Methods), the estimated proportion of people experiencing symptomatic COVID-19 going on to suffer Long-COVID were

similar: 14.5%, 5.1% and 2.2% for 4, 8- and 12-weeks duration respectively. While estimates could be inflated because early PCR testing was restricted to those more severely unwell, or if regular logging or test results encouraged a systematic bias in symptom reporting, Long-COVID may here be underestimated if individuals with prolonged symptoms were more likely to stop logging symptoms on the app. Our participant selection criteria were chosen to confidently identify cases, and upper and lower bounds for estimates given each exclusion criteria are presented in Supplementary Table 4. Symptom reporting rates through the study period for all users are also presented in Supplementary Table 6. Taken together, these data suggest that our estimates may be conservative. We had insufficient numbers to explore risk factors for disease over 2 months and were unable to analyse the impact of ethnicity due to incomplete data. In addition, the list of symptoms on the app is necessarily non-exhaustive, however, analysis of the free-text responses allowed us to highlight other symptoms present in Long-COVID, such as cardiac and neurological manifestations. With emerging evidence of ongoing myocardial inflammation and change in^{8,9} associated with COVID-19, this calls for specific studies of cardiac and neurological longer-term sequelae of COVID-19.

At the population level, it is critical to quantify the burden of Long-COVID to better assess its impact on the healthcare system and appropriately distribute resources. In our study, prospective logging of a wide range of symptoms allowed us to conclude that the proportion of people with symptomatic COVID-19 who experience prolonged symptoms is considerable, and relatively stable across three countries with different cultures. Whether looking at a four-week or an eight-week threshold for defining long duration, those experiencing Long-COVID were

consistently older, more likely to be female and to require hospital assessment than in the group reporting symptoms for a short period of time. Those going on to experience LC28 had multi-system disease from the start, supporting the need for holistic support¹⁰. While asthma was not reported as a factor of risk for hospitalisation in¹¹, its association with Long-COVID (LC28) warrants further investigation.

We found early disease features were predictive of duration. With only three features - number of symptoms in the first week, age and sex, we were able to accurately distinguish individuals with LC28 from those with short duration. Importantly, the model generalised well to the population reporting antibody testing. This important information could feature in highly needed targeted education material for both patients and healthcare providers and we present typical nomograms for use in clinical settings in Supplementary Figure 7. Moreover, the method could help determine at-risk groups and could be used to target early intervention trials and clinical service developments to support rehabilitation in primary and specialist care¹⁴ to alleviate Long-COVID and facilitate timely recovery.

Ethics: In the UK, the App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all subscribers provided consent. In Sweden, ethics approval for the study was provided by the central ethics committee (DNR 2020-01803).

Funding: Zoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. Support for this study was provided by the NIHR-funded Biomedical Research Centre based at GSTT NHS Foundation Trust. This work was supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare.

Investigators also received support from the Wellcome Trust, the MRC/BHF, Alzheimer's Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. ATC was supported in this work through a Stuart and Suzanne Steele MGH Research Scholar Award. CM is funded by the Chronic Disease Research Foundation and by the MRC AimHy project grant. LHN, DAD, ADJ,

ADS, CG, WL are supported by the Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz. JM was partially supported by the European Commission Horizon 2020 program (H2020-MSCA-IF-2015-703787). The work performed on the Swedish study is supported by grants from the Swedish Research Council, Swedish Heart-Lung Foundation and the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067).

Competing interests:

Zoe Global Limited co-developed the app *pro bono* for non-commercial purposes. Investigators received support from the Wellcome Trust, the MRC/BHF, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GUSTT NHS Foundation Trust in partnership with KCL. RD, JW, JCP, AM and SG work for Zoe Global Limited and TDS and PWF are consultants to Zoe Global Limited. LHN, DAD, JM, PWF and ATC previously participated as investigators on a diet study unrelated to this work that was supported by Zoe Global Ltd.

Data and materials availability: Data used in this study is available to bona fide researchers through UK Health Data Research using the following link

<https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259>

References

1. Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - Journal of the American Medical Association* vol. 324 782–793 (2020).
2. Sheehy, L. M. Considerations for postacute rehabilitation for survivors of COVID-19. *Journal of Medical Internet Research* vol. 22 (2020).
3. Alwan, N. A. A negative COVID-19 test does not mean recovery. *Nat.* 2020 5847820 (2020).
4. Menni, C. *et al.* Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat. Med.* **26**, 1037–1040 (2020).
5. Drew, D. A. *et al.* Rapid implementation of mobile technology for real-time epidemiology of COVID-19. *Science* (80-.). eabc0473 (2020) doi:10.1126/science.abc0473.
6. Sudre, C. H. *et al.* Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app. *medRxiv* 2020.06.12.20129056 (2020) doi:10.1101/2020.06.12.20129056.
7. Cirulli, E. T. *et al.* Long-term COVID-19 symptoms in a large unselected population. *medRxiv* (2020) doi:10.1101/2020.10.07.20208702.
8. Mitrani, R. D., Dabas, N. & Goldberger, J. J. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. *Hear. Rhythm* (2020) doi:10.1016/j.hrthm.2020.06.026.
9. Padda, I., Khehra, N., Jaferi, U. & Parmar, M. S. The Neurological Complexities and Prognosis of COVID-19. *SN Compr. Clin. Med.* (2020) doi:10.1007/s42399-020-00527-2.
10. *Living with Covid19*. <https://evidence.nihr.ac.uk/themedreview/living-with-covid19/>

(2020) doi:10.3310/themedreview_41169.

11. Robinson, L. B. *et al.* Title: COVID-19 severity in asthma patients: A multi-center matched cohort study. *medRxiv* 2020.10.02.20205724 (2020) doi:10.1101/2020.10.02.20205724.
12. Mahase, E. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint. *BMJ* **369**, m2512 (2020).
13. Beigel, J. H. *et al.* Remdesivir for the Treatment of Covid-19 — Preliminary Report. *N. Engl. J. Med.* (2020) doi:10.1056/nejmoa2007764.
14. Greenhalgh, T., Knight, M., A'Court, C., Buxton, M. & Husain, L. Management of post-acute covid-19 in primary care. *BMJ* **370**, (2020).
15. Drew, D. A. *et al.* Rapid implementation of mobile technology for real-time epidemiology of COVID-19. *Science* (80-.). (2020).
16. Spiel, C. *et al.* A Euclidean distance-based matching procedure for non randomized comparison studies. *Eur. Psychol.* **13**, 180–187 (2008).

Table 1. Characteristics of Individuals with COVID-19 by duration of symptoms, compared to matched sample testing negative for COVID-19. In statistical comparison, the short COVID group is the reference.

	Positive PCR test				Matched Negative sample
	Short (<10 days)	LC28 (>=28 days) (including LC56)	LC56 (>=56 days)	Overall	
Number	1591	558	189	4182	4182
GB/SE/US [numbers, %]	1365 / 139 / 87 85.8 / 8.7 / 5.5	466/57/35 83.5 / 10.2 / 6.3	165/12/12 87.3 / 6.3 / 6.3	3491 / 473 / 218 83.5 / 11.3 / 5.2	3882/131/169 92.8/3.1/4.1
Male (%)	32.7	20.3***	16.9*	28.5	28.5
Age (years) [median, IQR]	38 [29;49]	50 [39;57]***	52 [43;59]***	42 [32;53]	42 [32;53]
Age group (18-49/ 50-69/ >70)	1122/331/38 75.3 / 22.2 / 2.5	259/262/24 47.5 / 48.1 / 4.4	69/96/11 39.2 / 54.5 / 6.3	2627/1195/96 62.8 / 28.6 / 2.3	2821 / 1264/97 67.5 / 30.2 / 2.3
Obese (%)	23.8	27.6*	26.5	26.3	26.4
BMI (kg/m ²) [median, IQR]	25.5 [22.7;29.7]	26.1 [23.3;30.5]	25.9[23.3;30.5]	25.9[23.3;30.3]	25.9 [23.0;30.3]
Asthma (%)	7.7	15.8***	18.0***	10.0	13.7
Lung disease (%)	12.8	16.5**	15.9	13.6	13.7
Diabetes (%)	3.0	3.9	5.8*	2.9	2.8
Heart (%)	1.7	3.2**	4.8**	1.9	1.7

Kidney (%)	0.5	0.9	0.5	0.6	0.6
IMD (median decile - IQR)	7 [4;9]	7 [5;9]	7 [5;9]	7 [4;9]	7[5;9]***
IMD quintiles	64/75/334/132/634 5.2/6.1/27.0/10.7/51.2	23/23/86/49/240 5.5/5.5/20.4/11.6/57.0	10/9/26/18/88 6.6/6.0/17.2/11.9/58.3	158 / 194 /830/363 /1653 4.9 /6.1/26.0/11.4/51.7	118/193/895/376/2057 3.2/5.3/24.6/10.3/56.5
Visit to hospital (%)	7.0	31.5***	43.9***	13.9	4.1
Number of symptoms in the first week [median [IQR]]	5 [3;7]	7 [5-9]***	7 [5;9]***	6 [4;8]	3 [2;4]***

* indicates $p < 0.1$ ** < 0.05 *** < 0.01 when comparing to short covid. Comparison are performed with respect to the “short duration” within the positive group. Matched Negatives are compared to the overall positive population Mann Whitney U tests are performed for continuous variables and chi square tests are performed when comparing proportions.

Index of Multiple Deprivation (IMD) information is only available for app users from the UK who have entered a complete post code

Acronyms: GB – Great Britain / SE – Sweden / US – United States / IMD – Index of multiple deprivation

Figure 1. a) Distribution of duration of symptoms in COVID-19 – The coloured bars indicate the limits to define short, LC28 and LC56. The y-axis reports the normalised frequency of duration of symptoms. b) OR and 95% CI of LC28 with each successive decile compared to 20-30-year-olds

Figure 2 : Symptoms by duration. For each symptom (ordered from top to bottom by increasing frequency of occurrence) the median duration of report is presented by the total (hollowed) bar height, with associated interquartile range represented by the black line, for the short, LC28 and LC56 durations. The filled bars represent the number of times a report has been given. For both duration and number of reported days of symptoms, the x axis reflects the number of days. This highlights the differences in the symptoms in terms of their intermittence throughout the course of the disease. (Abbreviations DE – delirium, AP – Abdominal Pain, HV – Hoarse Voice, DI – Diarrhoea, CP – Chest Pain, SM – skipped meals, UMP – Unusual Muscle pains, FV – Fever, ST – Sore Throat, PC – Persistent Cough, LOS – Loss of smell, SOB – Shortness of breath, HA – Headache, FA – Fatigue)

Figure 3: Symptom correlates of long-COVID for LC28 (a) and LC56 (b) with correction for age and gender. c) Co-occurrence network of symptom pairs with the frequency of symptom report as the size of the node and the likelihood of symptom pair co-occurrence by the weight of the edge linking them. Edges representing a co-occurrence of less than 10% were removed. d) – Receiver Operating Characteristic (ROC) curve of the cross-validated full and reduced models on the PCR cohort. e)– ROC curve when training on the whole PCR cohort and testing on the antibody-positive cohort for the full (blue) and reduced (magenta) model. Random predictive probability is indicated in both panels as a dashed red line. (Abbreviations DE – delirium, AP – Abdominal Pain, HV – Hoarse Voice, DI – Diarrhoea, CP – Chest Pain, SM – skipped meals, UMP – Unusual Muscle pains, FV – Fever, ST – Sore Throat, PC – Persistent Cough, LOS – Loss of smell, SOB – Shortness of breath, HA – Headache, FA – Fatigue)

313

314